What is the recommended IVF ovarian stimulation regimen and the appropriate luteinizing hormone (LH) to follicle‑stimulating hormone (FSH) ratio?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 11, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

IVF Ovarian Stimulation Regimen and LH:FSH Ratio

For standard IVF ovarian stimulation, use a GnRH antagonist or long agonist protocol with gonadotropins (FSH with or without LH activity), starting at 150-225 IU FSH daily, with individualized dosing based on ovarian reserve markers (AMH, AFC) and patient age. The optimal exogenous LH:FSH ratio during controlled ovarian stimulation appears to be approximately 1:1 (75 IU LH:75 IU FSH per ampule), though this remains debated and depends on patient characteristics 1, 2, 3.

Stimulation Protocol Selection

GnRH antagonist protocols are strongly recommended for patients at high risk of ovarian hyperstimulation syndrome (OHSS), particularly those with polycystic ovary syndrome (PCOS), as they allow for a "freeze-all" strategy and reduce OHSS risk 4, 1. The antagonist protocol can be initiated at any point in the menstrual cycle ("random start stimulation"), which is particularly valuable in fertility preservation scenarios 5.

For standard responders, either GnRH agonist (long protocol starting in the luteal phase) or antagonist protocols are acceptable 6, 1. The long agonist protocol involves downregulation with GnRH agonist (e.g., nafarelin acetate 0.5 mg/day) starting in the luteal phase, followed by gonadotropin stimulation 6.

FSH Dosing Strategy

Starting FSH doses should be tailored to ovarian reserve:

  • Normal responders: 150 IU/day FSH
  • Poor responders (low AMH, advanced age): 225-300 IU/day FSH, though higher doses may not improve outcomes 1
  • High responders (PCOS, high AMH): 75-150 IU/day FSH to minimize OHSS risk 1

Critical caveat: If baseline FSH >20 IU/L, ovarian stimulation may not be appropriate, and natural cycle oocyte retrieval should be considered, especially in women under 35 years with normal antral follicle count 7.

The LH:FSH Ratio Controversy

Evidence Supporting LH Supplementation

The addition of LH activity to FSH during controlled ovarian stimulation improves oocyte and zygote numbers, with an optimal exogenous LH:FSH ratio around 1:1 (75:75 IU per ampule) 2, 3. A 2001 randomized trial found that while residual endogenous LH after GnRH agonist downregulation was adequate for ovarian response, adding exogenous LH improved implantation rates (28% with 75:75 IU FSH:LH vs. 19% with FSH alone) 3.

The relationship between LH:FSH ratio and outcomes is non-linear: fertilization rates improve with increasing LH:FSH ratios up to approximately 0.77, but decline when the ratio exceeds this threshold 2. This suggests a therapeutic window exists for LH supplementation.

Evidence Against Routine LH Use

However, more recent evidence challenges routine LH supplementation. A 2026 meta-analysis found that gonadotropins with LH activity versus rFSH alone probably result in little to no difference in live birth rates (RR=1.07,95% CI 0.96-1.18) and ongoing pregnancy rates (RR=1.03,95% CI 0.95-1.12), though they may slightly reduce the number of oocytes retrieved (MD=-0.50) 8.

In PCOS patients specifically, LH supplementation may be detrimental: a 2024 study found that while FSH+LH reduced total FSH requirements and cycle length, it resulted in significantly lower cumulative live birth rates compared to FSH alone (55.8% vs. 76.9%, p=0.044) 9.

Baseline FSH:LH Ratio as a Prognostic Marker

**An elevated baseline (day 3) FSH:LH ratio >2-3 in women with normal FSH levels (<10-12 IU/L) predicts poor ovarian response and lower pregnancy rates** 10, 11. Women with FSH:LH >3 have higher cycle cancellation rates (15% vs. 5.24%, p=0.0001), require higher total gonadotropin doses, and achieve lower peak estradiol levels 10. These patients may benefit from GnRH agonist protocols over antagonist protocols 11.

Practical Recommendations

Standard Protocol

  • Use purified FSH (urinary or recombinant) as the primary gonadotropin 6, 1
  • Consider adding LH activity (hMG or recombinant LH) in specific populations:
    • Women >35 years with suboptimal response to FSH alone
    • Poor responders with low baseline LH levels after GnRH agonist suppression
    • Patients with hypogonadotropic hypogonadism 1

PCOS Patients

  • Use FSH alone without LH supplementation in GnRH antagonist freeze-all protocols 9
  • Start with lower FSH doses (75-150 IU/day)
  • Consider metformin co-treatment to reduce OHSS risk 12

Monitoring and Trigger

  • Monitor with transvaginal ultrasound and serum estradiol 6
  • Trigger with 5,000-10,000 IU hCG when ≥3 follicles reach >17 mm with appropriately rising estradiol 6, 4
  • Retrieve oocytes 36-38 hours post-trigger 4

OHSS Prevention

The primary advantage of LH-containing gonadotropins is safety: they probably do not increase OHSS compared to FSH alone (RR=0.80,95% CI 0.61-1.03), making the benefit-risk balance favor their use for OHSS prevention 8.

Key Pitfalls to Avoid

  1. Do not use high-dose FSH (>225 IU/day) in poor responders expecting better outcomes—it increases costs without improving live birth rates 1

  2. Do not routinely add LH in PCOS patients undergoing antagonist protocols, as this may reduce cumulative live birth rates 9

  3. Do not ignore baseline FSH:LH ratio in women with "normal" FSH—a ratio >2-3 indicates subclinical diminished ovarian reserve requiring protocol adjustment 10, 11

  4. Do not exceed LH:FSH ratios of approximately 1:1 during stimulation, as higher ratios may impair fertilization 2

  5. In fertility preservation for cancer patients, prioritize speed over optimization—random start protocols with antagonists allow immediate initiation without waiting for cycle day 1 5

References

1
Research

ESHRE guideline: ovarian stimulation for IVF/ICSI: an update in 2025†.

Human reproduction (Oxford, England), 2026

11
Research

Impact of high basal FSH/LH ratio in women with normal FSH levels on in vitro fertilization outcomes.

Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology, 2013

Related Questions

What serum β‑hCG level at approximately day 9 after ovulation indicates a positive pregnancy test?
Can serum β‑hCG be negative on day 9 after an IVF embryo transfer and positive on day 12?
Should I repeat a urine pregnancy test now, given that my next appointment is in five days?
What basal follicle‑stimulating hormone (FSH) level on day 3 of the menstrual cycle indicates diminished ovarian reserve?
In a 51‑year‑old woman with an FSH level of 4.7 IU/L, what does this indicate about her menopausal status and what further evaluation should be performed?
What are the common complications of dialysis and how are they managed?
What are bibasal pulmonary distelettasic phenomena?
What is the step‑by‑step inpatient management plan for a child‑bearing‑age female patient with suspected lupus nephritis presenting with orthopnea and fluid overload?
Should an esophagogastroduodenoscopy (EGD) be performed for a patient with recurrent bloating, generalized abdominal pain, and post‑prandial diarrhea who has never had an upper endoscopy and has no alarm features?
Why does atomoxetine cause somnolence?
What is the recommended treatment approach for a patient in their late 80s?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.